These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 18499873)
1. For better or for worse: the future of antiplatelet therapy. Alvarez W Am J Health Syst Pharm; 2008 Jun; 65(11):1017. PubMed ID: 18499873 [No Abstract] [Full Text] [Related]
2. Prasugrel versus clopidogrel in patients with acute coronary syndromes. Wiviott SD; Braunwald E; McCabe CH; Montalescot G; Ruzyllo W; Gottlieb S; Neumann FJ; Ardissino D; De Servi S; Murphy SA; Riesmeyer J; Weerakkody G; Gibson CM; Antman EM; N Engl J Med; 2007 Nov; 357(20):2001-15. PubMed ID: 17982182 [TBL] [Abstract][Full Text] [Related]
3. Will prasugrel supersede clopidogrel for acute coronary syndromes? Hankey GJ; Eikelboom JW; Langton PE Med J Aust; 2008 Apr; 188(7):381-2. PubMed ID: 18393737 [No Abstract] [Full Text] [Related]
4. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Reese ES; Daniel Mullins C; Beitelshees AL; Onukwugha E Pharmacotherapy; 2012 Apr; 32(4):323-32. PubMed ID: 22461122 [TBL] [Abstract][Full Text] [Related]
5. Prasugrel versus clopidogrel. Serebruany V N Engl J Med; 2008 Mar; 358(12):1298; author reply 1299-301. PubMed ID: 18354110 [No Abstract] [Full Text] [Related]
6. A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome. Heart Advis; 2010 May; 13(5):6. PubMed ID: 22816152 [No Abstract] [Full Text] [Related]
7. Prasugrel: Clinical development and therapeutic application. Guerra DR; Tcheng JE Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231 [TBL] [Abstract][Full Text] [Related]
8. Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel. Rodriguez L; Conde D; Lalor N; Elissamburu P; Trivi M Am J Emerg Med; 2013 Aug; 31(8):1287. PubMed ID: 23769852 [No Abstract] [Full Text] [Related]
9. Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel. Lalor N; Conde D; Rodriguez L; Elissamburu P; Trivi M Am J Emerg Med; 2013 Aug; 31(8):1287-8. PubMed ID: 23806726 [No Abstract] [Full Text] [Related]
10. Clopidogrel versus prasugrel: times are changing, but not for everyone. Dobesh PP Pharmacotherapy; 2009 Dec; 29(12):1393-6. PubMed ID: 19947798 [No Abstract] [Full Text] [Related]
11. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380 [TBL] [Abstract][Full Text] [Related]
12. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Norgard NB; Abu-Fadel M Vasc Health Risk Manag; 2009; 5():873-82. PubMed ID: 19898643 [TBL] [Abstract][Full Text] [Related]
13. Prasugrel: a novel antiplatelet agent. Riley AB; Tafreshi MJ; Haber SL Am J Health Syst Pharm; 2008 Jun; 65(11):1019-28. PubMed ID: 18499874 [TBL] [Abstract][Full Text] [Related]
14. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?]. Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747 [No Abstract] [Full Text] [Related]
15. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM; Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975 [TBL] [Abstract][Full Text] [Related]
17. Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38". Serebruany VL Circulation; 2010 Aug; 122(8):e436; author reply e437. PubMed ID: 20733108 [No Abstract] [Full Text] [Related]
18. Prasugrel versus clopidogrel. von Lewinski F; Riggert J; Paulus W N Engl J Med; 2008 Mar; 358(12):1299; author reply 1299-301. PubMed ID: 18357639 [No Abstract] [Full Text] [Related]
19. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610 [TBL] [Abstract][Full Text] [Related]
20. Ischaemia versus bleeding: the art of clinical decision-making. Stone GW Lancet; 2009 Feb; 373(9665):695-6. PubMed ID: 19249613 [No Abstract] [Full Text] [Related] [Next] [New Search]